BioSpace News Archive

Provides Access to Industry-Leading Sequencing Lab and Plans for 10-Year Partnership with National Cancer Research Leaders

Management will host a conference call to discuss results at 8:30 a.m. ET on February 24th

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its fourth quarter and full-year 2020 financial results and provide a corporate update on Tuesday, February 23, 2021, after the close of the U.S. financial markets.

Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced it has appointed David S. Wilkes, M.D., dean, University of Virginia School of Medicine, and co-founder and chief scientific officer of biotech start-up ImmuneWorks to its board of directors.

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 6,896,552 common shares of Aeterna, at a price to the public of $1.45

- Global Phase IIb study to enrol approximately 312 patients, each of whom will receive one of three doses of MM-II or placebo - Primary endpoint is a reduction in pain from baseline as measured by WOMAC A pain scale at 12 weeks

Zomedica Corp. (NYSE American: ZOM), (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that the underwriter of its previously announced public offering of has exercised in full its over-allotment option to purchase an additional 13,697,368 common shares of Zomedica at a price to the public of $1.90 per share

Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President & Chief Executive Officer, will participate at the OIS Gene Therapy Innovation Showcase, taking place virtually on Thursday, February 18, 2021 from 12:00 PM to 3:00 PM CST.

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing a drug to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer, castrate-resistant prostate cancer and leukemias, today announced that Dr. Mark Erlander , chief executive officer of Cardiff Oncology will present at the upcoming LifeSci Partners Precision Oncology Day on February 17, 2021.

Maxwell Biosciences develops antiviral drugs, designed to be Zero-Day Therapeutics, which have been shown in preclinical studies to destroy a broad spectrum of viruses including rapidly evolving Coronavirus strains, announced the appointment of prominent New York University faculty member Kent Kirshenbaum, Ph.D., as the company’s Chief Scientific Officer.